Moreover, immunotherapy has been emerging as a promising therapy for TNBC in which tumor cells are killed by the immune system, namely, by immune checkpoint inhibitors (ICI), which include cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), programmed death receptor-ligand 1 (PD-L1) and programmed death receptor-1 (PD-1) as shown in Figure 4 [167]. Here, CTLA4 is linked to neoplasm.